JPRN-jRCT2080220730未知3 期
Multi-center, randomized, parallel-group, double-blind, placebo-controlled study to evaluate the safety and efficacy of lubiprostone in patients with chronic idiopathic constipation (CIC)
Sucampo Pharma, Ltd.0 个研究点目标入组 116 人开始时间: 2009年5月12日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 116
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •history of fewer than three spontaneous bowl movements (SBMs) per week for at least six months
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
Clinical trial in several centers in which patients are administrating randomly in parallel with treatment or placebo (control). Neither the researchers nor the patients know which treatment the patiens are receiving. Present clinical trial evaluates safety and clinical efficacy of intradermal immunotherapy with polymerised Phleum pratense, in patients with allergic rhino-conjunctivitis with or without mild to moderate asthma, sensitized to Phleum pratense pollen.Allergic patients to the pollen of Phleum pratense with allergic rhino-conjunctivitis with or without mild to moderate asthma.MedDRA version: 16.1Level: LLTClassification code 10001728Term: Allergic rhinoconjunctivitisSystem Organ Class: 100000004853EUCTR2014-000429-18-ESDIATER, Laboratorio de Diagnóstico y Aplicaciones Terapéuticas, S.A.174
已完成
不适用
Multicentre, parallel group, randomised, double blind study to investigate the efficacy of Montelukast (MK) + Fluticasone (FP) placebo versus Fluticasone + MK-placebo versus MK-placebo + FP-placebo in preschool children with asthma or asthma-like symptoms during a 3 months study periodAsthmaRespiratoryISRCTN38475879Merck Sharp and Dohme BV (Netherlands)150
进行中（未招募）
不适用
Multicenter, Randomized, Parallel-group, Double-blind, Placebo-controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate and Lithium as Monotherapy for up to 104 weeks Maintenance Treatment of Bipolar I Disorder in Adult Patients - SPaRCLeMedDRA version: 9.1Level: LLTClassification code 10004939Term: Bipolar I disorderBipolar I DisorderEUCTR2004-000915-25-LTAstraZeneca R&D Sodertalje2,100
进行中（未招募）
1 期
A multicenter, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the efficacy and safety of four different doses of Org 50081 in the treatment of moderate to severe vasomotor symptoms associated with the menopausemoderate to severe vasomotor symptoms associated with the menopauseMedDRA version: 7.0 Level: LLT Classification code 10020411EUCTR2004-000472-14-ESV Organon900
进行中（未招募）
不适用
A multicenter, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the efficacy and safety of four different doses of Org 50081 in the treatment of moderate to severe vasomotor symptoms associated with the menopausetreatment of moderate to severe vasomotor symptomsMedDRA version: 6.1Level: PTClassification code 10027304EUCTR2004-000469-36-ITORGANON ITALIA